GeoVax to Participate in Upcoming November Investor and Industry Events

ATLANTA, GA, Oct. 25, 2023 (GLOBE NEWSWIRE) -- via – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that members of its senior management team and other scientific representatives will participate in four upcoming investor and industry events during November. Event details are as follows:

Emerging Growth Conference, November 1-2, 2023, Virtual

Date/Time: November 2, 2023 at 3:55 p.m. ET

Title:           GeoVax Corporate Update

Speaker:     David Dodd, Chairman & CEO, GeoVax Labs, Inc.

For more information and to register to attend the GeoVax Presentation, please visit.

BIO-Europe, November 6-8, 2023, Munich, Germany

Senior GeoVax management will host one-on-one meetings with registered attendees. For more information, please visit . If interested in meeting with management at this event, please contact the company through the conference portal, or directly at .

Vaccines Summit 2023, November 13-15, 2023, Boston, MA

Date/Time: November 14, 2023 at 8:00 a.m. ET

Session Title: MVA-vectored multi-antigen COVID-19 vaccines induce protective immunity against SARS-CoV-2 variants spanning Alpha to Omicron in preclinical animal models

Speaker: Mukesh Kumar, PhD, Associate Professor, Department of Biology, Georgia State University

For more information on the conference, please visit.

World Vaccine Congress, West Coast, November 27-30, 2023, Santa Clara, CA

Date/Time: November 28, 2023 at 4:20 p.m. PT

Session Title: COVID-19 Vaccines for immunocompromised patients

Speaker: Don Diamond, Professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center

Date/Time: November 30, 2023 at 1:40 p.m. PT

Session Title: Design and evaluation of vaccines against hemorrhagic fevers using the MVA-VLP platform

Speaker: Jason Comer, PhD, Associate Professor, Department of Microbiology and Immunology, University of Texas Medical Branch

For more information on the conference, please visit.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for solid tumor cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin^®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine targeting high-risk immunocompromised patient populations. Currently in three Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, and as a booster vaccine in patients with chronic lymphocytic leukemia (CLL). In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information, visit our website: